How New Regulation of Laboratory-Developed Antimicrobial Susceptibility Tests Will Affect Infectious Diseases Clinical Practice
- 4 April 2024
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (5) , 1140-1147
Abstract
Antimicrobial resistance (AMR) affects 2.8 million Americans annually. AMR is identified through antimicrobial susceptibility testing (AST), but current and proposed regulatory policies from the United States Food and Drug Administration (FDA) jeopardize the future availability of AST for many microorganisms. Devices that perform AST must be cleared by the FDA using their susceptibility test interpretive criteria, also known as breakpoints. The FDA list of breakpoints is relatively short. Today, laboratories supplement FDA breakpoints using breakpoints published by the Clinical and Laboratory Standards Institute, using legacy devices and laboratory-developed tests (LDTs). FDA proposes to regulate LDTs, and with no FDA breakpoints for many drug–bug combinations, the risk is loss of AST for key clinical indications and stifling innovation in technology development. Effective solutions require collaboration between manufacturers, infectious diseases clinicians, pharmacists, laboratories, and the FDA.Keywords
This publication has 38 references indexed in Scilit:
- Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative InfectionsClinical Infectious Diseases, 2023
- Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018−2020)Diagnostic Microbiology and Infectious Disease, 2022
- Trimethoprim-sulfamethoxazole resistance patterns among Staphylococcus aureus in the United States, 2012–2018Infection Control & Hospital Epidemiology, 2022
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysisThe Lancet, 2022
- Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacyclinePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2021
- Trends and risk factors in the antibiotic management of skin and soft tissue infections in the United StatesJournal of Dermatological Treatment, 2021
- Daptomycin non-susceptible Enterococcus faecium in leukemia patients: Role of prior daptomycin exposureJournal of Infection, 2017
- Executive Summary: Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2012
- Off-label medication use in adult critical care patientsJournal of Critical Care, 2011
- Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary PracticesClinical Infectious Diseases, 2009